Aurobindo, Tergene to form JV for pneumonia vaccine

By: |
Hyderabad | Published: February 6, 2015 3:30 AM

Aurobindo Pharma has decided to form a joint venture with Hyderabad-based Tergene Biotech, a vaccine development company...

Aurobindo Pharma has decided to form a joint venture with Hyderabad-based Tergene Biotech, a vaccine development company, for developing pneumococcal conjugate vaccine (PCV).

“The board of directors of the company at its meeting, has approved the proposal for setting up a joint venture based in India. Tergene works on development of the pneumococcal conjugate vaccine,” Aurobindo Pharma said in a BSE filing.

Meanwhile, Aurobindo Pharma’s consolidated net profit declined 8% to Rs 384 crore in the third quarter ended December 31, 2014 compared to Rs 417 crore in the corresponding quarter of the previous financial year. Total income of the company, however, has gone up 48% to Rs 3,166 crore from Rs 2,140 crore. Commenting on the company’s performance, N Govindarajan, MD, said “We continue to grow our revenues and maintain profitability despite the absence of any exceptional upside.’’

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Finmin may review capital requirement of PSU banks after second quarter
2Industry for alternate sourcing destination as cost from China not going down: Signify Innovations
3Atmanirbhar Bharat campaign is a call to foster entrepreneurship not protectionism: Venkaiah Naidu